Filter Results:
(4,453)
Show Results For
- All HBS Web
(4,453)
- People (16)
- News (1,494)
- Research (2,163)
- Events (3)
- Multimedia (130)
- Faculty Publications (1,511)
Show Results For
- All HBS Web
(4,453)
- People (16)
- News (1,494)
- Research (2,163)
- Events (3)
- Multimedia (130)
- Faculty Publications (1,511)
- August 2024
- Case
Pioneering Pain Management: CWC Alliance Combats the Opioid Epidemic
By: Susanna Gallani, Karen L. Sedatole and Sarah Mehta
Set in March 2024, this case is about CWC Alliance (CWC), a nonprofit working to prevent opioid addiction in the U.S. Founder Cammie Wolf Rice launched CWC in 2018 after her son, Christopher Wolf, died of a heroin overdose. Wolf’s dependence on opioids stemmed from a... View Details
Keywords: Health; Innovation and Invention; Jobs and Positions; Social Enterprise; Strategy; Health Industry; United States; Georgia (state, US); Atlanta
Gallani, Susanna, Karen L. Sedatole, and Sarah Mehta. "Pioneering Pain Management: CWC Alliance Combats the Opioid Epidemic." Harvard Business School Case 125-012, August 2024.
- 10 Jul 2020
- News
Sutter Health’s Request to Delay $575 Million Settlement Is Denied
- 03 Aug 2022
- News
How Will Amazon Approach U.S. Primary Care?
- December 2016
- Article
Selective Regulator Decoupling and Organizations' Strategic Responses
By: Jonas Heese, Ranjani Krishnan and Frank Moers
Organizations often respond to institutional pressures by symbolically adopting policies and procedures but decoupling them from actual practice. Literature has examined why organizations decouple from regulatory pressures. In this study, we argue that decoupling... View Details
Keywords: Regulator Leniency; Beneficence; Mispricing; Upcoding; Nonprofit Organizations; Health Care and Treatment; Revenue; Health Industry
Heese, Jonas, Ranjani Krishnan, and Frank Moers. "Selective Regulator Decoupling and Organizations' Strategic Responses." Academy of Management Journal 59, no. 6 (December 2016). (Selected for Best Paper Proceedings of the 2015 Academy of Management Annual Meeting. Winner of the Healthcare Management Division of the Academy of Management 2015 Best Paper Award.)
- 20 Jul 2021
- News
Rewriting the Social Contract
- 02 Aug 2021
- Blog Post
Uncovering the Virtual Advantage at Humana
afterwards with those unable to attend live. The Everchanging Environment of Healthcare and Recruiting Humana operates its’ business in an environment where the only constant is change. Advances in medicine, changes to policy, and the... View Details
- March 2018 (Revised January 2019)
- Case
Gilead Mexico
By: Michael Chu and V. Kasturi Rangan
With a breakthrough cure for Hepatitis C listing in the U.S. at $1,000/pill, Gilead must now solve the issue of making it available to patients across the world, much as it did for its blockbuster HIV/AIDS antiretrovirals. For Erik Musalem, the new general manager of... View Details
Chu, Michael, and V. Kasturi Rangan. "Gilead Mexico." Harvard Business School Case 318-111, March 2018. (Revised January 2019.)
- 02 Sep 2014
- First Look
First Look: September 2
legacy labor and health care costs-is seriously incomplete and that GM's share collapsed for many of the same reasons that many of the other... View Details
Keywords: Sean Silverthorne
- 29 Jan 2019
- First Look
New Research and Ideas, January 29, 2019
generating consensus on the specifics of benefit-based taxation. Download working paper: https://www.hbs.edu/faculty/Pages/item.aspx?num=55548 Harvard Business School Case 818-017 Pricing PatientPing In 2017, Jay Desai, the CEO View Details
Keywords: Dina Gerdeman
- December 1998 (Revised September 1999)
- Case
Novartis: Betting on Life Sciences
By: Ray A. Goldberg, Carin-Isabel Knoop and Srinivas Sunder
The merger of Ciba-Geigy and Sandoz produced genomic-based synergies for health care, agribusiness, and nutritional supplements. How to build on the strength of the individual divisions and provide synergies that would continue Novartis' leadership role is the question... View Details
Keywords: Mergers and Acquisitions; Business Divisions; Health Care and Treatment; Leadership; Product Positioning; Science-Based Business; Corporate Strategy; Pharmaceutical Industry
Goldberg, Ray A., Carin-Isabel Knoop, and Srinivas Sunder. "Novartis: Betting on Life Sciences." Harvard Business School Case 599-076, December 1998. (Revised September 1999.)
- May 2014 (Revised March 2017)
- Case
Unilever's Lifebuoy in India: Implementing the Sustainability Plan
Unilever's new Global Brand VP must not only revitalize Lifebuoy soap's sagging market performance, but simultaneously impact the health of one billion people worldwide. The latter challenge comes from Unilever's new CEO who has introduced the Unilever Sustainable... View Details
Keywords: Multinational Management; Corporate Social Responsibility; Strategy Implementation; Marketing Strategy; Mission And Purpose; Change Management; International Business; Global; Fast-moving Consumer Goods; Soap; Corporate Social Responsibility and Impact; Health Care and Treatment; Environmental Sustainability; Global Strategy; Developing Countries and Economies; Beauty and Cosmetics Industry; Health Industry; India
Bartlett, Christopher A. "Unilever's Lifebuoy in India: Implementing the Sustainability Plan." Harvard Business School Case 914-417, May 2014. (Revised March 2017.)
- 13 Apr 2017
- News
What Precision Medicine Can Learn from the NFL
- June 2004
- Case
Medical Technology Industry and Japan (A), The
In a five-year effort, the Health Industry Manufacturers Association (HIMA) tried to influence government health policy in Japan. In 1993, HIMA mobilized in response to fears the Japanese government was planning to target the U.S. medical devices industry. The case... View Details
Keywords: Health Care and Treatment; Policy; Globalized Markets and Industries; Government and Politics; Medical Devices and Supplies Industry; Japan; United States
Watkins, Michael D., and Terri Zavada. "Medical Technology Industry and Japan (A), The." Harvard Business School Case 904-018, June 2004.
- 09 Jan 2015
- News
Report: Don't let integration cause physician micromanagement
- Program
Program for Leadership Development
the careful selection of living group members and new HBS case studies to professional executive coaching for individuals and teams, every aspect is designed to foster collaborative learning and accelerate... View Details
- 29 Jul 2021
- News
Medical debt was cut nearly in half in states that expanded Medicaid
- October 2023
- Article
What Does the Inflation Reduction Act Mean for Patients and Physicians?
By: Amitabh Chandra and Benedic Ippolito
The debate around prescription drug measures in the recently passed U.S. Inflation Reduction Act (IRA), which limit some patients’ out-of-pocket costs, has not fully addressed their effect on physicians and patients via their effect on payers. Reducing patients’ costs... View Details
Chandra, Amitabh, and Benedic Ippolito. "What Does the Inflation Reduction Act Mean for Patients and Physicians?" NEJM Catalyst Innovations in Care Delivery 4, no. 10 (October 2023).
- July 2019 (Revised May 2020)
- Supplement
Piramal e-Swasthya (C): A New Name, Bigger Scope, and Public-Private Partnerships
By: Rosabeth Moss Kanter and Joyce J. Kim
In 2010, Anand Piramal acquired the Health Management Research Institute (HMRI), a healthcare venture, and merged it with his original digital healthcare startup Piramal e-Swasthya (PeS), so that PeS became Piramal Swasthya. After acquiring HMRI, Piramal Swasthya... View Details
Keywords: Entrepreneur; Healthcare; Innovation; Emerging Economies; Scaling; Social Enterprise; Entrepreneurship; Health Care and Treatment; Innovation and Management; Emerging Markets; Growth and Development; Organizational Change and Adaptation; Partners and Partnerships; India
Kanter, Rosabeth Moss, and Joyce J. Kim. "Piramal e-Swasthya (C): A New Name, Bigger Scope, and Public-Private Partnerships." Harvard Business School Supplement 320-012, July 2019. (Revised May 2020.)
- May 2002 (Revised October 2005)
- Case
Marketing Antidepressants: Prozac and Paxil
By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)